Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma

American Journal of Pathology

Volumn 161, Issue 6, 2002, Pages 2295-2309

  Zhang, Lin ^a   Yang, Nuo ^a   Conejo Garcia, Jose Ramon ^a   Mohamed, Alisha ^a   Benencia, Fabian ^a   Rubin, Stephen C ^a   Allman, David ^b   Coukos, George ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GREEN FLUORESCENT PROTEIN; ISOPROTEIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASCITES; AUTOCRINE EFFECT; CANCER CELL; CANCER GROWTH; CELL SELECTION; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR IMMUNITY; VACCINATION;

EID: 0036899148     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64505-1     Document Type: Article

References (73)

1. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257
2. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J: Vascular-specific growth factors and blood vessel formation. Nature 2000, 407:242-248
3. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100: 57-70
4. Robinson CJ, Stringer SE: The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001, 114:853-865
5. Shima DT, Kuroki M, Deutsch U, Ng YS, Adamis AP, D'Amore PA: The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. J Biol Chem 1996, 271:3877-3883
6. Zhang L, Conejo-Garcia JR, Yang N, Huang W, Mohamed-Hadley A, Yao W, Benencia F, Coukos G: Different effects of glucose starvation on expression and stability of VEGF mRNA isoforms in murine ovarian cancer cells. Biochem Biophys Res Commun 2002, 292:860-868
7. Park JE, Keller GA, Ferrara N: The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993, 4:1317-1326
8. Stalmans I, Ng YS, Rohan R, Fruttiger M, Bouche A, Yuce A, Fujisawa H, Hermans B, Shani M, Jansen S, Hicklin D, Anderson DJ, Gardiner T, Hammes HP, Moons L, Dewerchin M, Collen D, Carmeliet P, D'Amore PA: Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest 2002, 109:327-336
9. Ng YS, Rohan R, Sunday ME, Demello DE, D'Amore PA: Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn 2001, 220:112-121
10. Grunstein J, Masbad JJ, Hickey R, Giordano F, Johnson RS: Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature. Mol Cell Biol 2000, 20:7282-7291
11. Yu JL, Rak JW, Klement G, Kerbel RS: Vascular endothelial growth factor isoform expression as a determinant of blood vessel patterning in human melanoma xenografts. Cancer Res 2002, 62:1838-1846
12. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992, 255:989-991
13. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, Bohlen P: Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992, 187:1579-1586
14. Gluzman-Poltorak Z, Cohen T, Herzog Y, Neufeld G: Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165. J Biol Chem 2000, 275:18040-18045
15. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M: Neuropilin-1 is expressed by endothelial and tumor cells as an isoformspecific receptor for vascular endothelial growth factor. Cell 1998, 92:735-745
16. Shen GH, Ghazizadeh M, Kawanami O, Shimizu H, Jin E, Araki T, Sugisaki Y: Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 2000, 83:196-203
17. Abulafia O, Triest WE, Sherer DM: Angiogenesis in malignancies of the female genital tract. Gynecol Oncol 1999, 72:220-231
18. Junker K: Prognostic factors in stage I/II non-small cell lung cancer. Lung Cancer 2001, 33(Suppl 1):S17-S24
19. Gasparini G: Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 2000, 5(Suppl 1):S37-S44
20. Chung YS, Maeda K, Sowa M: Prognostic value of angiogenesis in gastrointestinal tumours. Eur J Cancer 1996, 32A:2501-2505
21. Tomisawa M, Tokunaga T, Oshika Y, Tsuchida T, Fukushima Y, Sato H, Kijima H, Yamazaki H, Ueyama Y, Tamaoki N, Nakamura M: Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer 1999, 35:133-137
22. Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, Twentyman PR, Smith SK: Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995, 87:506-516
23. Speirs V, Atkin SL: Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours. Br J Cancer 1999, 80:898-903
24. Tian X, Song S, Wu J, Meng L, Dong Z, Shou C: Vascular endothelial growth factor: Acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803. Biochem Biophys Res Commun 2001, 286:505-512
25. Itakura J, Ishiwata T, Shen B, Kornmann M, Korc M: Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 2000, 85:27-34
26. Liu B, Earl HM, Baban D, Shoaibi M, Fabra A, Kerr DJ, Seymour LW: Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem Biophys Res Commun 1995, 217:721-727
27. Langer I, Vertongen P, Perret J, Fontaine J, Atassi G, Robberecht P: Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in human neuroblastomas. Med Pediatr Oncol 2000, 34: 386-393
28. Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L, Hicklin DJ, Tateno M, Bohlen P, Moore MA, Rafii S: Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA 2001, 98:10857-10862
29. Koistinen P, Siitonen T, Mantymaa P, Saily M, Kinnula V, Savolainen ER, Soini Y: Regulation of the acute myeloid leukemia cell line OCI/AML-2 by endothelial nitric oxide synthase under the control of a vascular endothelial growth factor signaling system. Leukemia 2001, 15:1433-1441
30. Herold-Mende C, Steiner HH, Andl T, Riede D, Buttler A, Reisser C, Fusenig NE, Mueller MM: Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells. Lab Invest 1999, 79:1573-1582
31. Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS: Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 2001, 98:1904-1913
32. Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, Wu Y, Chadburn A, Hyjek E, Gill M, Hicklin DJ, Witte L, Moore MA, Rafii S: Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000, 106:511-521
33. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996, 2:1096-1103
34. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, Carbone DP: Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998, 92:4150-4166
35. Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics, 2001. CA Cancer J Clin 2001, 51:15-36
36. Ogawa S, Kaku T, Kobayashi H, Hirakawa T, Ohishi Y, Kinukawa N, Nakano H: Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: A special review for clear cell adenocarcinoma. Cancer Lett 2002, 176:111-118
37. Brustmann H, Naude S: Vascular endothelial growth factor expression in serous ovarian carcinoma: Relationship with high mitotic activity and high FIGO stage. Gynecol Oncol 2002, 84:47-52
38. Santin AD, Hermonat PL, Ravaggi A, Cannon MJ, Pecorelli S, Parham GP: Secretion of vascular endothelial growth factor in ovarian cancer. Eur J Gynaecol Oncol 1999, 20:177-181
39. Boss EA, Massuger LF, Thomas CM, Geurts-Moespot A, Boonstra H, Sweep CG: Vascular endothelial growth factor in ovarian cyst fluid. Cancer 2001, 91:371-377
40. Mesiano S, Ferrara N, Jaffe RB: Role of vascular endothelial growth factor in ovarian cancer: Inhibition of ascites formation by immunoneutralization. Am J Pathol 1998, 153:1249-1256
41. Chen CA, Cheng WF, Lee CN, Chen TM, Kung CC, Hsieh FJ, Hsieh CY: Serum vascular endothelial growth factor in epithelial ovarian neoplasms: Correlation with patient survival. Gynecol Oncol 1999, 74:235-240
42. Hartenbach EM, Olson TA, Goswitz JJ, Mohanraj D, Twiggs LB, Carson LF, Ramakrishnan S: Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett 1997, 121:169-175
43. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, Persons DL, Smith PG, Terranova PF: Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000, 21:585-591
44. Pear WS, Nolan GP, Scott ML, Baltimore D: Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993, 90:8392-8396
45. Tomayko MM, Reynolds CP: Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989, 24:148-154
46. Graff BA, Bjornaes I, Rofstad EK: Microvascular permeability of human melanoma xenografts to macromolecules: Relationships to tumor volumetric growth rate, tumor angiogenesis, and VEGF expression. Microvasc Res 2001, 61:187-198
47. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, Schuler G: An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999, 223:77-92
48. Powell SK, Kaloss M, Burimski I, Weaver L, Long Z, Lyons R, McGarrity GJ, Otto E: In vitro analysis of transformation potential associated with retroviral vector insertions. Hum Gene Ther 1999, 10:2123-2132
49. Steff AM, Fortin M, Arguin C, Hugo P: Detection of a decrease in green fluorescent protein fluorescence for the monitoring of cell death: An assay amenable to high-throughput screening technologies. Cytometry 2001, 45:237-243
50. Maxwell PH, Pugh CW, Ratcliffe PJ: Activation of the HIF pathway in cancer. Curr Opin Genet Dev 2001, 11:293-299
51. Vikhanskaya F, Bani MR, Borsotti P, Ghilardi C, Ceruti R, Ghisleni G, Marabese M, Giavazzi R, Broggini M, Taraboletti G: p73 overexpression increases VEGF and reduces thrombospondin-1 production: Implications for tumor angiogenesis. Oncogene 2001, 20:7293-7300
52. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, Dillehay LE, Madan A, Semenza GL, Bedi A: Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000, 14:34-44
53. Wiener JR, Nakano K, Kruzelock RP, Bucana CD, Bast Jr RC, Gallick GE: Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model. Clin Cancer Res 1999, 5:2164-2170
54. Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, Unger C, Marme D, Gastl G: Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999, 85:178-187
55. Grunstein J, Roberts WG, Mathieu-Costello O, Hanahan D, Johnson RS: Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res 1999, 59:1592-1598
56. Harris SR, Schoeffner DJ, Yoshiji H, Thorgeirsson UP: Tumor growth enhancing effects of vascular endothelial growth factor are associated with increased nitric oxide synthase activity and inhibition of apoptosis in human breast carcinoma xenografts. Cancer Lett 2002, 179:95-101
57. Duyndam MC, Hilhorst MC, Schluper HM, Verheul HM, van Diest PJ, Kraal G, Pinedo HM, Boven E: Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts. Am J Pathol 2002, 160:537-548
58. Kagi D, Ledermann B, Burki K, Zinkernagel RM, Hengartner H: Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol 1996, 14:207-232
59. Coukos G, Rubin SC: Chemotherapy resistance in ovarian cancer: New molecular perspectives. Obstet Gynecol 1998, 91:783-792
60. Katoh O, Takahashi T, Oguri T, Kuramoto K, Mihara K, Kobayashi M, Hirata S, Watanabe H: Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an antiapoptotic factor. Cancer Res 1998, 58:5565-5569
61. Ferrara N: Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol 2001, 280:C1358-C1366
62. Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, Meng G, Hong K, Marsters JC, Ferrara N: VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002, 417: 954-958
63. Bachelder RE, Crago A, Chung J, Wendt MA, Shaw LM, Robinson G, Mercurio AM: Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 2001, 61:5736-5740
64. Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP: Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999, 5:2963-2970
65. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI: Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000, 6:1755-1766
66. Tromp SC, oude Egbrink MG, Dings RP, van Velzen S, Slaaf DW, Hillen HF, Tangelder GJ, Reneman RS, Griffioen AW: Tumor angiogenesis factors reduce leukocyte adhesion in vivo. Int Immunol 2000, 12:671-676
67. Detmar M: Molecular regulation of angiogenesis in the skin. J Invest Dermatol 1996, 106:207-208
68. Skelton D, Satake N, Kohn DB: The enhanced green fluorescent protein (eGFP) is minimally immunogenic in C57BL/6 mice. Gene Ther 2001, 8:1813-1814
69. Schlienger K, Chu CS, Woo EY, Rivers P, Toll AJ, Hudson B, Maus MV, Riley JL, Choi Y, Coukos G, Kaiser LR, Rubin SC, Levine BL, Carroll RG, June CH: TRANCE matured dendritic cells generate MHC class-I restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res (in press)
70. Hoffman RM: Visualization of GFP-expressing tumors and metastasis in vivo. Biotechniques 2001, 30:1016-1024
71. Hoffman RM: Orthotopic transplant mouse models with green fluorescent protein-expressing cancer cells to visualize metastasis and angiogenesis. Cancer Metastasis Rev 1998, 17:271-277
72. Paley PJ: Angiogenesis in ovarian cancer: Molecular pathology and therapeutic strategies. Curr Oncol Rep 2002, 4:165-174
73. Papetti M, Herman IM: Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 2002, 282:C947-C970